


## **IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

1. (previously presented) A method of treating a patient having leukemia, lymphoma, carcinoma, sarcoma, breast cancer, lung cancer, head and neck cancer, rectal cancer, or bladder cancer comprising administering to the patient in need thereof an effective amount of a compound of general formula (I):



(I)

(i) wherein  $X^+$  is selected from the group consisting of  $N^+(R_1, R_2, R_3)$  and  $P^+(R_1, R_2, R_3)$ , wherein  $R_1, R_2$  and  $R_3$ , which are the same or different, are selected from the group consisting of hydrogen and  $C_1$ - $C_9$  straight or branched alkyl groups,  $-CH=NH(NH_2)$ ,  $-NH_2$ , and  $-OH$ ; with the proviso that at least one of  $R_1, R_2$  and  $R_3$  is different from hydrogen;

(ii) Z is selected from the group consisting of

-OR<sub>4</sub>,  
-OCOOR<sub>4</sub>,  
-OCONHR<sub>4</sub>,  
-OCSNHR<sub>4</sub>,  
-OCSOR<sub>4</sub>,  
-NHR<sub>4</sub>,  
-NHCOR<sub>4</sub>,  
-NHCSR<sub>4</sub>,  
-NHCOOR<sub>4</sub>,  
-NHCSOR<sub>4</sub>,  
-NHCONHR<sub>4</sub>,  
-NHCSNHR<sub>4</sub>,  
-NHSOR<sub>4</sub>,

- NHSONHR<sub>4</sub>,
- NHSO<sub>2</sub>R<sub>4</sub>,
- NHSO<sub>2</sub>NHR<sub>4</sub>, and
- SR<sub>4</sub>,

wherein R<sub>4</sub> is a C<sub>2</sub>-C<sub>20</sub> saturated or unsaturated, straight or branched alkyl group;

(iii) Y<sup>-</sup> is selected from the group consisting of -COO<sup>-</sup>, -PO<sub>3</sub>H, -OPO<sub>3</sub>H<sup>-</sup>, and tetrazolate-5-yl; a salt, enantiomer or racemic mixture thereof.

2. (previously presented) The method according to claim 1, wherein in the compound of formula (I), independently of one another,

- X is trimethylammonium or a group N<sup>+</sup>(R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>);
- R<sub>4</sub> is selected from the group consisting of heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and eicosyl;
- Z is a ureido (-NHCONHR<sub>4</sub>) or carbamate (-NHCOOR<sub>4</sub>, -OCONHR<sub>4</sub>) group.

3. (currently amended) The method according to claim 2, wherein the compound is selected from the group consisting of

- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-aminobutyrate;
- ~~— R,S-4-quinuclidinium-3-(tetradecyloxy-carbonyl)-oxybutyrate;~~
- R,S-4-trimethylammonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-oxybutyric acid chloride;
- R,S-4-trimethylphosphonium-3-(nonylcarbamoyl)-oxybutyrate;
- R,S-4-trimethylammonium-3-(octyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-(nonyloxycarbonyl)-aminobutyrate;
- R,S-4-trimethylammonium-3-octyloxybutyrate;
- R,S-4-trimethylammonium-3-tetradecyloxybutyrate;
- R,S-1-guanidinium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;
- R,S-1-trimethylammonium-2-tetradecyloxy-3-(tetrazolate-5-yl)-propane;

- ~~— R,S-3-quinuclidinium-2-(tetradecyloxy-carbonyl)-oxy-1-propanephosphonate monobasic;~~
- R,S-3-trimethylammonium-2-(nonylaminocarbonyl)-oxy-1-propanephosphonate monobasic;
  - R-4-trimethylammonium-3-(tetradecylcarbomoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(undecylcarbomoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(heptylcarbomoyl)-aminobutyrate;
  - R,S-4-trimethylammonium-3-(nonylthiocarbomoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(noncarbomoyl)-aminobutyrate;
  - S-4-trimethylammonium-3-(nonylcarbomoyl)-aminobutyrate;
  - S-4-trimethylammonium-3-(tetradecylcarbomoyl)-aminobutyrate;
  - R,S-4-trimethylammonium-3-tetradecylaminobutyrate;
  - R,S-4-trimethylammonium-3-octylaminobutyrate;
  - R,S-4-trimethylammonium-3-(decansulfonyl)-aminobutyrate;
  - R,S-4-trimethylammonium-3-(nonylsulfamoyl)-aminobutyrate;
  - S-4-trimethylammonium-3-(dodecansulfonyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(dodecansulfonyl)-aminobutyrate;
  - S-4-trimethylammonium-3-(undecylsulfamoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(undecylsulfamoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(dodecylcarbomoyl)-aminobutyrate;
  - R-4-trimethylammonium-3-(10-phenoxydecylcarbomoyl)-aminobutyrate;
- and
- R-4-trimethylammonium-3-(trans-b-styrenesulfonyl)-aminobutyrate.

4. (previously presented) The method according to claim 1, wherein the compound is R-4-trimethylammonium-3-(tetradecylcarbomoyl)-aminobutyrate.

Claim 5 (canceled)

6. (previously presented) A therapeutic preparation containing a compound according to claim 1 in combination with an antitumor agent selected from the group consisting of anthracyclines, alkylating agents and cytokines, for simultaneous separate or sequential administration to a tumor patient.

7. (previously presented) A therapeutic preparation according to claim 6, wherein the antitumor agent is an anthracycline.

8. (original) A preparation according to claim 7, wherein the anthracycline is doxorubicin.

9. (previously presented) A therapeutic preparation containing a compound according to claim 1 in combination with an antitumor agent selected from the group consisting of cytotoxic or cytostatic compounds, antimetabolites, hormone antagonists, alkaloids and antibiotics, for simultaneous separate or sequential administration to a tumor patient.

10. (previously presented) A therapeutic preparation containing a compound according to claim 1 in combination with an antitumor agent which is a peptide, for simultaneous separate or sequential administration to a tumor patient.

11. (previously presented) The method according to claim 1, wherein a hepatocarcinoma patient is treated.

12. (previously presented) The method according to claim 1, wherein a leukemia patient is treated.